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In this issue of the Journal, Kojima et al report that standard-dose statin therapy provided incremental clinical benefit in a population of Japanese patients with CHD and DM. 6 They assessed the Multicenter Study for Aggressive Lipidlowering Strategy by HMG-CoA Reductase Inhibitor in patients with CHD (MUSAHI) database, which includes 486 patients with acute myocardial infarction (AMI) and 533 patients with stable angina who underwent percutaneous coronary intervention (PCI). The patients with AMI were randomly assigned within 96 h of onset and patients with stable angina were randomly assigned within 48 h of PCI to standard therapy with any statin or to standard therapy without statin. Finally, a total of 1,016 patients with CHD were randomized to either a statin group (n=503) or a non-statin group (n=513); this study population consisted of 301 diabetic patients and 715 non-diabetic patients. Statin therapy equally decreased LDL-cholesterol levels to approximately 100 mg/dl in both diabetic and non-diabetic patients, and reduced the incidence of major adverse cardiovascular and cerebrovascular events. Interestingly, statin therapy was more effective in diabetic patients (number needed to treat (NNT) =8, relative risk reduction (RRR) 67%) compared with non-diabetic patients (NNT 30, RRR 24%), although it achieved LDL-cholesterol levels of approximately 100 mg/dl in both groups, suggesting the efficacy of standard-dose statin treatment. However, there were several biases in the study. The study subjects consisted of 2 different populations who had either experienced AMI or not, and such a heterogeneous population may affect the prognosis of diabetic and non-diabetic groups because previous AMI is a major risk factor for recurrent cardiovascular disease. In addition, the study population was relatively small, which may lead to overestimation of the difference between the statin and non-statin treatment groups.
In a Western population, aggressive lipid-lowering by high-dose atorvastatin therapy further reduced the risk of cardiovascular events in patients with CHD and metabolic syndrome compared with low-dose atorvastatin. 7 In the Japanese population, there are several studies that indicate that aggressive lipid lowering therapy might be beneficial in high-risk patients. 8, 9 In the secondary prevention study by Kojima et al, however, mild lipid-lowering by statins dramatically reduced the risk of cardiac events in high-risk patients and this result urges us to discuss further the adequate level of LDL-cholesterol for preventing recurrence of cardiovascular disease in Japanese high-risk patients.
Furthermore, Kojima et al demonstrated that statin treatment only reduced the incidence of unstable angina, defined as recurrent symptomatic ischemia with emergency hospitalization, in both diabetic and non-diabetic groups. Therefore, we need to carefully interpret the huge impact of statin therapy in diabetic patients, because this endpoint was diagnosed on the basis of the physician's decision and asymptomatic myocardial ischemia occurs often in diabetic patients with cardiac autonomic neuropathy. Nevertheless, these preferable results suggest that standard-dose statin therapy stabilizes so-called vulnerable plaque. Clinical and preclinical studies also suggest that statins have various effects that are independent of LDL-cholesterol lowering (ie, pleiotropic effects). Besides statins suppressing cholesterol biosynthesis by inhib-
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iting its rate-limiting enzyme, an HMG-CoA reductase, statins also decrease intermediate isoprenoid metabolites, which in turn induces anti-inflammatory effects that may favor stability and hinder the thrombogenicity of plaques. 10 The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (Jupiter) demonstrated that rosuvastatin reduced the risk of cardiovascular disease in patients with higher systemic inflammation and without hyperlipidemia, 11 indicating the clinical significance of the anti-inflammatory effect of statins.
Recently, DM has been thought of as a chronic inflammatory state, as well as obesity, metabolic syndrome, insulin resistance and subsequent atherosclerosis. Kojima et al found remarkable risk reduction in diabetic subjects with CHD, although statin treatment reduced LDL-cholesterol levels equally in both diabetic and non-diabetic subjects. Therefore, a possible mechanism for the incremental beneficial effect of statins in diabetic patients is the anti-inflammatory and antioxidant effects beyond cholesterol lowering. Moreover, acute coronary syndrome (ACS), caused by the rupture of vulnerable plaque, is thought of as an extreme inflammatory state. The PROVE IT-TIMI22 trial showed that intensive statin therapy early after ACS (within 10 days) reduced the clinical events at 30 days, consistent with early pleiotropic effects of statin, and this aggressive treatment provided long-term reduction of clinical events compared with standard therapy. 12 Okazaki et al reported that early and aggressive lipidlowering by atorvastatin in a Japanese population of patients with ACS significantly diminished plaque volume. 8 The MUSASHI database includes 483 patients with AMI who received statin within 96 h of the onset of AMI. Statin therapy early after ACS may suppress systemic and local inflammation and contribute to improving the prognosis of high-risk patients.
In the Japanese population, whether aggressive lipid-lowering is beneficial in high-risk patients remains unclear. The secondary prevention study by Kojima et al demonstrates that mild LDL-cholesterol lowering by standard-dose statin therapy can remarkably reduce the risk in Japanese diabetic patients with CHD through, at least in part, pleiotropic effects. Further studies with larger populations are needed to clarify the ideal LDL-cholesterol level in Japanese high-risk patients.
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